Filana Therapeutics, Inc.
FLNAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeFilana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Valued at $48.8M, FLNA is a micro-cap name in its sector. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Market Cap
$48.8M
Beta
-0.74
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.59
EPS (Fwd)
—
ROE
-79.6%
ROA
-24.9%
Cash
$86.6M
Total Debt
$0
Free CF
$16.1M
52W Change
-60.9%
Annual Financials
Cash vs Debt
Where FLNA stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, FLNA finished 40.11% below its 150-day moving average ($1.82) and 50.68% below its 200-day moving average ($2.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FLNA overbought or oversold?
At the July 15, 2026 close, FLNA's RSI(14) was 40.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Filana Therapeutics, Inc. reports $86.6M in cash and $0 in total debt. Annual free cash flow of $16.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -79.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -0.74 suggests FLNA is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Filana Therapeutics, Inc. and its sector.